1-Hydroxy-7-azabenzotriazole Pharma Grade is charged as a racemization-suppressing coupling additive in the production of synthetic peptide drug substances that are subsequently formulated into tablets, capsules, granules, and sterile injectable preparations. The material is not retained as the active moiety in the finished dosage form; its role is confined to the activation of carboxyl components during peptide bond formation. In a solution-phase coupling line for injectable peptide APIs such as leuprolide acetate or triptorelin acetate, HOAt is typically added at 1.0–1.3 molar equivalents relative to the carboxyl-terminal amino acid, while N,N′-diisopropylcarbodiimide is maintained at 1.0–1.1 molar equivalents. The reaction is run in anhydrous N,N-dimethylformamide or N-methyl-2-pyrrolidone under nitrogen in a jacketed glass-lined reactor equipped with bottom-discharge valve and PTFE-lined piping. The protected peptide segment concentration is held between 0.15 M and 0.35 M, and the coupling temperature is kept at −5°C to +5°C for racemization-sensitive segments, with slow warming to 20–25°C for less hindered sites. The use of HOAt instead of 1-hydroxybenzotriazole is driven by the electron-withdrawing effect of the 7-aza nitrogen, which increases leaving-group reactivity and suppresses epimerization of urethane-protected amino acids. Reaction progress is monitored by reversed-phase high-performance liquid chromatography with UV detection at 210–220 nm. After coupling, the DIC-derived N,N′-diisopropylurea is removed by solvent exchange and filtration, and the crude peptide is precipitated from cold methyl tert-butyl ether. The crude product is then purified by preparative RP-HPLC on a C18 column using acetonitrile/0.1% trifluoroacetic acid mobile phases, followed by lyophilization. Release of the injectable-grade peptide drug substance includes purity by HPLC area normalization ≥99.0%, total related substances ≤1.0%, residual solvent compliance with ICH Q3C, bacterial endotoxins per USP <85>, and bioburden control prior to sterile filtration. HOAt does not appear on the finished product label; instead it is controlled as a process-related impurity through the drug substance specification and cleaning validation.

What Limits HOAt Stoichiometry in Solid-Phase Oral Peptide API Synthesis?

In Fmoc solid-phase peptide synthesis for oral peptide APIs such as semaglutide, HOAt is activated with DIC at 0–5°C before addition to the resin, because moisture ingress above 0.05% Karl Fischer in DMF promotes anhydride formation and reduces available coupling sites. Resin substitution is typically set between 0.40 mmol/g and 0.65 mmol/g for a 2-chlorotrityl resin or Rink amide resin, depending on the C-terminal functionality. For a 100 mmol batch, the standard coupling protocol uses Fmoc-amino acid, HOAt, and DIC at 4:4:4 molar equivalents relative to free resin amine, with a single coupling time of 45–90 minutes at 20–30°C. Hindered residues such as valine, isoleucine, and arginine require double coupling or a shift to 6:6:6 equivalents, and the temperature may be lowered to 10–15°C to minimize epimerization while extending the reaction to 2–4 hours. Fmoc deprotection is performed with 20% piperidine in DMF, and the dibenzofulvene-piperidine adduct is monitored at 304 nm to confirm cumulative deprotection efficiency. After the final amino acid, cleavage with trifluoroacetic acid/triisopropylsilane/water at 95:2.5:2.5 releases the side-chain-deprotected peptide; the crude product is precipitated in cold diethyl ether or methyl tert-butyl ether and isolated by centrifugation. At pilot scale, a 500 mmol fixed-bed reactor with polytetrafluoroethylene frits and overhead nitrogen agitation is used, and poor solvent penetration in highly resin-loaded columns is the main process bottleneck. Batch records include resin substitution verification, coupling efficiency by Kaiser test or chloranil test, and acylation ratio data after each cycle. The terminal oral solid dosage form may include the peptide API with an absorption enhancer such as sodium N-[8-(2-hydroxybenzoyl) amino] caprylate in a tablet, but the HOAt-derived peptide drug substance must first meet residual solvent limits, elemental impurities per ICH Q3D, and process-related impurity thresholds.

When an oral peptide API manufactured with HOAt is formulated into delayed-release granules for capsule filling, the drug substance is generally preprocessed by spray drying or lyophilization to achieve a flowable particle size distribution before dry blending with mannitol, microcrystalline cellulose, and crospovidone. The granulation step is performed in a fluidized-bed granulator with an inlet air temperature of 60–70°C, product temperature of 28–35°C, and a spray rate of 10–25 g/min per kg of batch, using an aqueous binder solution of hypromellose 3 mPa·s or povidone K30 at 5–10% w/w. Because the peptide active is present at low weight fraction, the granule formulation must pass blend uniformity with RSD ≤5.0% and content uniformity per USP <905>. Enteric-coated multiparticulates are produced by spraying an aqueous dispersion of methacrylic acid-ethyl acrylate copolymer Type A onto the granules; the coating chamber is held at 25–35% relative humidity to avoid polymer coalescence. The API process-related impurity from HOAt is not expected in the finished granule, but a purge factor is developed during process validation to demonstrate removal across precipitation, chromatography, and lyophilization. Stability studies for such granules typically run at 25°C/60% RH and 40°C/75% RH with testing for related substances, assay, and moisture. The capsule filling line uses a dosator-style or tamping-pin encapsulation machine; fill weight control is maintained at ±5% of the target capsule fill mass.

When Desmopressin Acetate Tablets Are Manufactured from HOAt-Handled Peptide Intermediates

Desmopressin acetate tablets at 0.1 mg and 0.2 mg label claim are considered a low-dose oral peptide solid dosage form where the drug substance may be synthesized using solution-phase or solid-phase coupling conditions in which HOAt serves as the racemization-suppressing additive. The API is jet-milled to a target particle size D90 below 10 µm before geometric blending with lactose monohydrate, potato starch, and magnesium stearate at 0.5–1.0% w/w. Direct compression is run on a rotary tablet press with 7 mm round tooling at a compression force of 6–12 kN, target tablet hardness of 2–4 kp, and friability below 1.0% per USP <1216>. The low-dose blend requires dilution steps not exceeding 1:10 in a bin blender, and blend uniformity is confirmed by near-infrared spectroscopy with root mean square error of prediction below 5.0% relative. Tablet content uniformity is tested per USP <905> with acceptance value ≤15.0. Process-related HOAt is controlled at the drug substance stage by reversed-phase HPLC or LC-MS/MS; the finished tablet release specification does not include HOAt as an analytical target unless required by regional regulatory agreements. Packaging consists of cold-form aluminium/aluminium blister with desiccant because the peptide is moisture-sensitive; storage conditions are stated as 15–25°C and protection from light. Disintegration testing per USP <701> and dissolution testing per USP <711> in 500 mL of water at 37°C with paddle speed 50 rpm are applied depending on the pharmacopoeial monograph.

Residual HOAt and Process-Related Impurity Control for Injectable Depot Formulations

Injectable long-acting peptide products such as triptorelin pamoate or leuprolide acetate depot microspheres are produced from peptide drug substances in which HOAt is consumed during the coupling step and removed before final formulation. The drug substance is dissolved in water or dilute acetic acid, filtered through a 0.22 µm sterilizing-grade filter, and emulsified with a solution of poly(lactide-co-glycolide) in dichloromethane at 10–15% w/w using an in-line static mixer or high-shear rotor-stator at 1000–3000 rpm. The organic solvent is extracted into an aqueous continuous phase containing polyvinyl alcohol, and the microspheres are hardened by solvent evaporation at 20–25°C with controlled stirring. Final lyophilization of the microsphere suspension or of the peptide solution before encapsulation is performed with a conservative cycle: freezing at −45°C for 4 hours, primary drying at −20°C and 50–100 mTorr for 24–48 hours, and secondary drying at 20°C for 5 hours. Residual HOAt and related acylation by-products in the drug substance are separated by preparative RP-HPLC; method validation establishes an LOQ at or below 0.05 mg/g relative to the peptide drug substance, and acceptance criteria are set by toxicological qualification per ICH Q3A. Sterility testing follows USP <71>, bacterial endotoxins USP <85>, and particulate matter USP <788> for injectable products. The microsphere formulation is released for in vitro drug release testing using a sample-and-separate method in phosphate-buffered saline pH 7.4 at 37°C; release profiles are typically biphasic with a low initial burst and sustained release over 1–3 months. Finished product storage at 2–8°C and protected from light is specified due to the thermolabile peptide and poly(lactide-co-glycolide) matrix.